Completed PHASE4 NCT00618176

Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort

Sponsor: Ministry of Science and Technology of the People´s Republic of China

Interventions Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP) Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP) Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)

Updated 5 times since 2017 Last updated: Mar 21, 2008 Started: Jan 31, 2005 Primary completion: Sep 30, 2006

Listed as NCT00618176, this PHASE4 trial focuses on HIV Infections and remains completed. Sponsored by Ministry of Science and Technology of the People´s Republic of China, it has been updated 5 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ministry of Science and Technology of the People´s Republic of China
Peking Union Medical College

Data source: Peking Union Medical College

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China